Gabapentin-induced exacerbation of myasthenia gravis.
Sheen
Volney L
VL
Ohaegbulam
Chima
C
Rencus
Tal
T
Tandon
Deepak
D
D000368:Aged; D000588:Amines / Q000009:adverse effects* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000077206:Gabapentin; D005764:Gastroesophageal Reflux / Q000150:complications; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000150:complications*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects* / Q000627:therapeutic use
D000588:Amines; D002800:Cholinesterase Inhibitors; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D011729:Pyridostigmine Bromide